Core Viewpoint - Zacks Premium offers various tools and resources to help investors make informed decisions and enhance their confidence in stock market investments [1]. Summary by Category Zacks Style Scores - Zacks Style Scores are indicators designed to assist investors in selecting stocks with the highest potential to outperform the market within the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2]. Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, aiming to find attractive investment opportunities before the market recognizes their true value [3]. Growth Score - The Growth Style Score emphasizes a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable long-term growth [4]. Momentum Score - The Momentum Style Score helps investors capitalize on price trends, utilizing metrics like one-week price changes and monthly earnings estimate changes to determine optimal entry points for stocks [5]. VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive assessment of stocks based on their weighted styles, thus identifying companies with the best overall investment potential [6]. Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.64% since 1988, significantly outperforming the S&P 500 [7][8]. Stock to Watch: Labcorp Holdings - Labcorp Holdings, a leading healthcare diagnostics company, has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating strong growth potential. The company is projected to achieve year-over-year earnings growth of 11.9% for the current fiscal year, with upward revisions in earnings estimates from analysts [11][12].

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, aiding investors in selecting stocks with high potential for market outperformance [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on value, growth, and momentum characteristics, with higher scores indicating better chances of outperforming the market [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Evaluates a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks experiencing upward or downward trends in price or earnings, utilizing factors like one-week price change and monthly earnings estimate changes [5] VGM Score - Combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum [6] Zacks Rank Integration - The Zacks Rank is a proprietary model based on earnings estimate revisions, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [7] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9] Stock Highlight: Labcorp Holdings - Labcorp Holdings is a leading healthcare diagnostics company, known for its comprehensive clinical laboratory services and drug development support [11] - Currently rated 3 (Hold) on the Zacks Rank, Labcorp has a VGM Score of A and a Momentum Style Score of B, with shares increasing by 9.4% over the past four weeks [12] - Analysts have revised Labcorp's earnings estimate upwards, with the Zacks Consensus Estimate rising by $0.25 to $16.30 per share, and an average earnings surprise of +2.5% [12][13]

Company Overview - Labcorp Holdings, headquartered in Burlington, NC, is a leading healthcare diagnostics company that provides comprehensive clinical laboratory services and end-to-end drug development support [11] - In 2015, Labcorp acquired Covance, a drug development services company that offers a wide range of early-stage and late-stage product development services primarily to the pharmaceutical and biotechnology industries [11] Investment Potential - Labcorp is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating strong potential for growth investors [12] - The company is forecasted to achieve year-over-year earnings growth of 11.9% for the current fiscal year, supported by positive revisions from analysts [12] - Eight analysts have revised their earnings estimates higher in the last 60 days for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.25 to $16.30 per share [12] - Labcorp has an average earnings surprise of +2.5%, further enhancing its attractiveness to investors [12] Summary of Style Scores - Labcorp's Growth Style Score is rated A, indicating strong financial strength and a positive future outlook [12] - The combination of a solid Zacks Rank and top-tier Growth and VGM Style Scores positions Labcorp as a noteworthy option for investors [13]

Company Overview - Labcorp Holdings, headquartered in Burlington, NC, is a leading healthcare diagnostics company that provides comprehensive clinical laboratory services and end-to-end drug development support [12] - In 2015, Labcorp acquired Covance, a drug development services company that offers a wide range of early-stage and late-stage product development services primarily to the pharmaceutical and biotechnology industries [12] Investment Ratings - Labcorp is currently rated as a 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [13] - The company has a Value Style Score of B, supported by attractive valuation metrics such as a forward P/E ratio of 16.64, which may appeal to value investors [13] Earnings Estimates - In the last 60 days, eight analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.25 to $16.30 per share [13] - Labcorp has demonstrated an average earnings surprise of +2.5%, indicating a positive trend in earnings performance [13] Investment Potential - With a solid Zacks Rank and top-tier Value and VGM Style Scores, Labcorp is recommended to be on investors' short list for potential investment opportunities [14]

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence and knowledge [1] - The Zacks Style Scores are designed to complement the Zacks Rank, providing additional stock ratings based on value, growth, and momentum [3][4][5][6][7] Zacks Style Scores - Each stock is rated from A to F based on value, growth, and momentum characteristics, with A being the highest score [4] - The Value Score identifies attractive and discounted stocks using ratios like P/E and Price/Sales [4] - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings [5] - The Momentum Score helps investors capitalize on price trends, utilizing factors like price changes and earnings estimate revisions [6] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stock selection [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks averaging a +23.75% annual return since 1988, outperforming the S&P 500 [8] - There can be over 800 top-rated stocks available, making it essential to use Style Scores for effective selection [9] - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] Stock to Watch: Labcorp Holdings - Labcorp Holdings is a leading healthcare diagnostics company, known for its clinical laboratory services and drug development support [12] - Currently rated 3 (Hold) on the Zacks Rank, Labcorp has a VGM Score of A and a Momentum Style Score of A, with shares up 1.5% in the past four weeks [13] - Recent upward revisions in earnings estimates for fiscal 2025 have increased the Zacks Consensus Estimate by $0.22 to $16.27 per share, with an average earnings surprise of +2.5% [13][14]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, helping investors identify securities likely to outperform the market in the short term [2][3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to find those with sustainable growth potential [4] Momentum Score - The Momentum Style Score assesses stocks based on recent price changes and earnings estimate trends, aiding investors in timing their purchases [5] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive indicator for stock selection [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988 [7][8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9][10] Company Spotlight: Labcorp Holdings - Labcorp Holdings is a leading healthcare diagnostics company, known for its clinical laboratory services and drug development support, particularly after acquiring Covance in 2015 [11] - Labcorp has a Zacks Rank of 3 (Hold) and a VGM Score of A, with a Value Style Score of B, supported by a forward P/E ratio of 16.09 [12] - Recent upward revisions in earnings estimates indicate positive momentum, with the Zacks Consensus Estimate for fiscal 2025 increasing by $0.22 to $16.27 per share [12][13]

Company Overview - Labcorp Holdings, Inc. is a leading healthcare diagnostics company providing comprehensive clinical laboratory services and end-to-end drug development support [12] - The company acquired Covance in 2015, enhancing its capabilities in drug development services for the pharmaceutical and biotechnology industries [12] Investment Analysis - Labcorp has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a moderate investment potential [13] - The Momentum Style Score for Labcorp is B, with shares increasing by 9.9% over the past four weeks [13] - For fiscal 2025, eight analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.04 to $16.05 per share [13] - Labcorp has an average earnings surprise of 2.3%, suggesting a positive trend in earnings performance [13] Investment Recommendation - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Labcorp is recommended for investors' consideration [14]